Advertisement
Australia markets close in 26 minutes
  • ALL ORDS

    8,015.10
    -61.80 (-0.77%)
     
  • ASX 200

    7,776.50
    -62.30 (-0.79%)
     
  • AUD/USD

    0.6685
    +0.0035 (+0.52%)
     
  • OIL

    81.29
    +0.46 (+0.57%)
     
  • GOLD

    2,327.40
    -3.40 (-0.15%)
     
  • Bitcoin AUD

    92,152.16
    +827.70 (+0.91%)
     
  • CMC Crypto 200

    1,276.89
    +27.77 (+2.22%)
     
  • AUD/EUR

    0.6244
    +0.0043 (+0.69%)
     
  • AUD/NZD

    1.0926
    +0.0069 (+0.64%)
     
  • NZX 50

    11,835.02
    +118.58 (+1.01%)
     
  • NASDAQ

    19,701.13
    +226.51 (+1.16%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • Dow Jones

    39,112.16
    -299.05 (-0.76%)
     
  • DAX

    18,177.62
    -147.96 (-0.81%)
     
  • Hang Seng

    18,089.20
    +16.30 (+0.09%)
     
  • NIKKEI 225

    39,710.86
    +537.71 (+1.37%)
     

Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024

Oxurion NV
Oxurion NV

Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024

Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting.

All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

ADVERTISEMENT

Please contact for additional information:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
pascal.ghoson@oxurion.com

Backstage Communication
Jurgen Vluijmans
Partner
jurgen@backstagecom.be

Attachment